Clinical Trials Browser

INDUSTRY × Adenocarcinoma Of Esophagus × 90 days × Clear all

Adenocarcinoma Of Esophagus, Gastrointestinal Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT07090499 2026-03-19

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Phase 1 Recruiting

310 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

Clinical Trials

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

STAR-221

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

HERIZON-GEA-01

EDGE-Gastric

TroFuse-015

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

SAPHIR

A Study of KK2269 in Adult Participants With Solid Tumors

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors